Determination of serum prostate-specific antigen-α1-antichymotrypsin complex for diagnosis of prostate cancer in Japanese cases

Scandinavian Journal of Urology and Nephrology

Volumn 35, Issue 1, 2001, Pages 5-10

  Kuriyama, M ^a   Abrahamsson, P A ^b   Imai, K I ^c   Akimoto, S ^d   Deguchi, N ^e   Shichiri, Y ^f   Sugiyama, Y ^a   Niwa, T ^g   Inoue, T ^h  

^a GIFU UNIVERSITY   (Japan)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Atagawa Onsen Hospital   (Japan)

^d Inoue Memorial Hospital   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f KYOTO UNIVERSITY   (Japan)

^g NAGOYA UNIVERSITY HOSPITAL   (Japan)

^h Inoue Hospital   (Japan)

Author keywords

Diagnosis; Diagnostic gray zone; Prostate cancer; PSA; PSA ACT; ROC

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; CORRELATION FUNCTION; DIAGNOSTIC ACCURACY; ENZYME IMMUNOASSAY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ALPHA 1-ANTICHYMOTRYPSIN; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOENZYME TECHNIQUES; INCIDENCE; JAPAN; MALE; MIDDLE AGED; PROBABILITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0035093442     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365590151030660     Document Type: Article

References (29)

1. Prostate-specific antigen as a tumor marker in prostate cancer
2. Molecular forms of serum prostate-specific antigen: The clinical usefulness of percent free PSA to discriminate prostate cancer from BPH
3. 1-antichymotrypsin complex (PSA-ACT) in blood
4. 1-antichymotrypsin determination in prostate cancer
5. Second Stanford Conference on international standardization of prostate-specific antigen immunoassay; September 1 and 2, 1994
6. 1-antichymotrypsin-complex value in diagnosis of prostate cancer
7. Purification of a human prostate specific antigen
8. Serum prostate-specific antigen in a community-based population of healthy men; establishment of age-specific reference ranges
9. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
10. Evaluation of free serum prostate-specific antigen to improve specificity of prostate cancer screening
11. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan
12. Significance of free to total PSA ratio in men slightly elevated serum PSA levels: A cooperative study
13. 1-antichymotrypsin-complexed PSA, and free/total PSA ratio using the specific and sensitive enzyme-linked immunosorbent assay "E-plate EIKEN PSA"
14. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. A prospective multicenter clinical trial
15. Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer
16. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen
17. The evaluation of PSA molecular forms, molecular ratio, and PSAD in the cases showing slightly elevated serum PSA values for screening prostate cancer
18. A prostate antigen in sera of prostate cancer patients
19. Enzyme immunoassay for detection of serum prostate antigen and prostatic acid phosphatase-binding globulins
20. Circulating antibody to prostate antigen in patients with prostatic cancer
21. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer
22. 1-antichymotrypsin
23. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum
24. Measurement of complexed PSA improves specificity for early detection of prostate cancer
25. 1-antichymotrypsin complex in serum by monoclonal antibody based enzyme immunoassay
26. Relationship of prostate-specific antigen levels to prostate volume and age in mass screening subjects
27. Relationship between diurnal rhythm of serum testosterone and two prostatic markers (PSA and PAP) in untreated prostate cancer